China: China And Switzerland: The FTA And Medical Devices

Last Updated: 20 June 2014
Article by Christoph Huegli and Nathan Kaiser


This article outlines the implications of the new Free Trade Agreement (FTA) between China and Switzerland in relation to the trade in medical devices. There will be a special focus on the impact on tariffs, the applicable rules of origin, and the reduction of technical barriers to trade.

The FTA was signed on 6 July 2013, and is expected to enter into force in the second half of 2014.1 The agreement's general aim is to improve mutual market access for goods and services. The agreement is also to enhance legal security for the protection of intellectual property and bilateral economic exchange. It shall further contribute to sustainable development, and deepen bilateral cooperation between the parties. 2

For goods in particular, such as medical devices, the FTA widely reduces and eliminates tariffs. It includes a set of rules of origin, so as to determine whether or not a product falls under its protection. It specifies provisions for trade facilitation and a set of trade remedies in case of threat of serious damage to either party's domestic market. It also includes regulations on technical barriers to trade (TBT), plus sanitary and phytosanitary (SPS) measures.3

Tariff Reductions


The FTA specifies that the parties are to eliminate or reduce customs duties imposed on the importation of products originating from either party.4 This does not include equivalents to internal taxes, anti-dumping or countervailing duties or fees and charges of any kind imposed in connection with the importation commensurate with the cost of services rendered.5

Customs duties for most industrial products exported from Switzerland to China are to be gradually adjusted over time (depending on the product in 0-, 5-, 10-, 12- and 15-year periods), whereas industrial products exported from China to Switzerland are instantly freed of customs duties. The explanation for this difference is China's claim to have a specific need for adjustment given the sometimes substantially higher level of tariffs than Switzerland.6

The schedules for tariff reductions for particular products are set out in the FTA's Annex I and its Appendixes I (for China) and II (for Switzerland).

China Adjustment Specifics (Appendix I to Annex I)

The periodical reduction rates for tariffs on products entering into China are to be applied to the "most-favoured nation" rate applied on 1 January 2010, included in the charts of the Appendixes as the "base rate".7 The most-favored nation rate means the lowest customs duties rates granted to any other trade partner by China. Upon entry into force of the FTA, there will be an instant drop of these rates of customs duties for all goods to a new "preferential rate", with the exception of those goods that have no preference. The preferential rate is an exclusive rate granted under the FTA by China to Switzerland. There will be another drop of this preferential rate on 1 January of the following year and from then on annually on this date.8

Switzerland Adjustment Specifics (Appendix II to Annex I)

As mentioned above, in contrast to China, there is no gradual adjustment of customs duties on products entering into Switzerland. All customs duties will instantly, as categorized in Appendix II, either be classified under:

  1. Category A (Completely freed);
  2. Categories B1, B3 and C (Be partially dismantled); or
  3. Category D (Will have no preference at all); upon entering into the agreement.

In contrast to the customs duties and reductions imposed by China, those specified by Switzerland aren't defined as percentages but as absolute sums in CHF.9

Medical Devices

According to the World Health Organisation (WHO), the definition of a medical device is as follows: any instrument, apparatus, implement, machine, appliance, implant, in vitro reagent or calibrator, software, material or other similar or related article, intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the specific purposes of; diagnosis, prevention, monitoring, treatment or alleviation of disease, diagnosis, monitoring, treatment, alleviation of or compensation for an injury, investigation, replacement, modification, or support of the anatomy or of a physiological process, supporting or sustaining life, control of conception, disinfection of medical devices, providing information for medical purposes by means of in vitro examination of specimens derived from the human body and which does not achieve its primary intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means.10

Appendixes I and II to Annex I list a number of categories of products that fit the WHO definition. 11

China (Appendix I to Annex I)

Appendix I for China includes 28 categories of products that can be qualified as medical devices. The description includes instruments and appliances used in medical, surgical, dental and veterinary sciences, including scintigraphic apparatus, other electro-medical apparatus and sight-testing instruments. Of the listed categories, 12 are immediately freed from customs duties (Category A), nine are gradually freed over five years (Category B) and seven will be freed after the completion of 10 years (Category C1). Most of these are subject to a base rate of four percent under the most-favoured nation rate of 1 January 2010, which will be eliminated for all of these products at the end of the respective transitional period. None are subject to only partial dismantling of the tariff rate.12

Switzerland (Appendix II to Annex I)

Appendix II for Switzerland lists 13 categories of products that can be qualified as medical devices. They all fall into Category A, which means customs duties are all eliminated upon entry into force of the FTA.13

Rules of Origin

As the FTA only grants preference to products originating in either Switzerland or China,14 it includes a set of rules of origin.15

Originating products must alternatively fulfill one of the following requirements:

  1. They must be wholly obtained in a party; or
  2. They must be produced in a party exclusively using originating materials of one or both parties; or
  3. Where non-originating materials are used in the production process, the non-originating materials must undergo a substantial transformation in a party.16

In the last case, a certain relation of the value of non-originating materials used and the value of the ex-works price of the product must be maintained. This relation is called "VNM%".17

Annex II lists product-specific rules for products to have preference under the FTA. These are applicable to products of either party. Annex II refers to the International Convention on the Harmonized Commodity Description and Coding System in which medical devices are classified under Chapter 90. The only product-specific rule in Annex II for this chapter is the VNM%.18 The specified VNM% for medical products is 55 percent. The value of non-originating materials used in the production process of medical devices can not exceed 55 percent of the value of the ex-works price, in order for it to have preference under the FTA.

Trade Facilitation

Chapter 4 of the FTA includes a set of rules on trade facilitation and customs procedures. It commits the parties to implement customs procedures in compliance with international standards and to make the laws and regulations relevant for the movement of goods available to the public. The parties also agree to base customs controls on objective risk analyses and to issue binding information on tariffs and country of origin to economic operators.19

Trade Remedies

Chapter 5 of the FTA lists a set of trade remedies that includes anti-dumping measures, subsidies and countervailing measures. For these the FTA refers to the relevant WTO provisions.20 In addition to the WTO provisions, the FTA sets forth that the parties have to consult each other with a view to finding an acceptable solution before making use of the measures provided in Chapter 5 of the agreement.21

The FTA, under certain conditions, also allows for the application of bilateral safeguard measures. Notably, if tariff concessions of the FTA lead to a new level of imports that could cause serious damage to a domestic industry, tariff concessions may be temporarily suspended.22

Reductions of Technical Barriers to Trade (TBT)

A big technical barrier to trade with China for medical devices is the costly and long process for products to be approved by the authorities in order for them to be sold.

New and Incorporated Regulations

Chapter 6 of the FTA addresses technical barriers to trade (TBT). Its objective is to facilitate bilateral trade and access to respective markets for goods falling under the scope of the chapter.23 Furthermore, the parties shall strengthen their technical cooperation in various areas, in view of increasing the mutual understanding of their respective systems.24

The FTA incorporates the existing WTO Agreement on Technical Barriers to Trade (WTO TBT Agreement), mutatis mutandis,25 and includes rules that go further than the TBT Agreement, e.g. it specifically names standards issued by the International Organization for Standardization (ISO), the International Electrotechnical Commission (IEC), the International Telecommunication Union (ITU) and the Codex Alimentarius Commission that are to be considered relevant for goods traded under the FTA.26

Along with the FTA there are several side agreements concerning TBT, such as the Agreement on Cooperation in the Area of TBT and SPS, and the Agreement on Cooperation in the Area of Certification and Accreditation.27


The WTO TBT Agreement expresses that the parties are to ensure that conformity assessment results of other members are recognized, provided there is confidence that the procedures are equivalent, even if different.28 In coherence the FTA stipulates that the parties are to promote the accreditation of conformity assessment bodies on the basis of relevant standards and guides of the ISO and IEC, and to encourage the mutual acceptance of conformity assessment results of such accredited bodies.29

The side agreements on certification and accreditation and TBT and SPS further mean the parties are to cooperate on compulsory and voluntary certification schemes and accreditation,30 to promote communication and cooperation between the respective competent authorities and certification and accreditation bodies of the two parties31 and for these bodies to carry out cooperation activities under the side agreements.32

In order for these cooperation schemes to reach their determined affect, the FTA also establishes a Sub-Committee on Technical Barriers to Trade under the Joint Committee that specifically monitors the implementations of the rules concerning TBT.33

According to the SECO, the extent of the practical implications of this new set of rules and its facilitations for certification and accreditation of products can't yet be determined. An improvement of the current situation, however, is anticipated.34


Concludingly the FTA will bring notable trade advantages for both parties. Tariffs will be widely eliminated or reduced on both sides, especially for medical devices. Tariffs on products being imported into Switzerland are instantly upon entry into force of the FTA eliminated, and tariffs on products being imported into China are also eliminated, albeit over a five- to 10-year transition period.

The rules of origin of the FTA specify where non-originating materials are used in the production process, these must undergo a substantial transformation. For medical devices, their value in relation to the ex works price of the product must be no more than 55 percent (VNM%).

As for the reduction of non-tariff barriers, the certification and accreditation process for medical products is expected to improve by the establishment of a set of rules to further the cooperation and communication between the parties. Such rules shall, amongst others, include the promotion of accreditation of conformity assessment bodies and the recognition of their results, the adoption of four international standards and the introduction of a sub committee on TBT.


1According to information provided by the Swiss State Secretariat for Economic Affairs (SECO) (22.8.2013)

2 Factsheet FTA CH-China, p. 1

3 Factsheet FTA CH-China, p. 1

4 FTA art. 2.3.2.

5 FTA art. 2.3.1.(a), (b), (c), the terms are consistent with the GATT (General Agreement on Tariffs and Trade) 1994 and the relevant rules therein (paragraph 2 Art. III, Art. VI and Art. VIII) apply to (a), (b), (c), respectively.

6 Factsheet FTA CH-China, p. 2

7 FTA art. 2.4.1.

8 Appendix I to Annex I of the FTA, A. explanatory notes

9 Appendix II to Annex I of the FTA, A. explanatory notes

11 They are coded with the ciphers 9018 and following, for the first four digits of the tariff line code number in both Appendixes I and II to Annex I.

12 Appendix I to Annex I of the FTA, A. explanatory notes and p. 522-524

13 Appendix I to Annex II of the FTA, A. explanatory notes and p. 384-385. In contrast to China, Appendix II for Switzerland doesn't include an overhead title. It does however follow the same coding starting with the digits 9018 and above

14 FTA art. 1.2

15 FTA art. 3.1

16 FTA art. 3.2 (a), (c)

17 FTA art. 3.2 (b) icw art. 3.4.3

18 Annex II of the FTA, p. 1 icw p. 16 and FTA art. 4.9

19 Factsheet FTA CH-China, p. 3

20 Factsheet FTA CH-China, p. 3

21 Factsheet FTA CH-China, p. 3

22 FTA art. 3.1

23 FTA art. 6.1.(a)

24 FTA art. 6.5

25 FTA art. 6.2

26 FTA art. 6.4 icw TBT Agreement art. 2.4

27 SPS meaning Sanitary and phytosanitary measures in the sense of FTA chapter 7

28 TBT Agreement art. 6.1

29 FTA art. 6.5.(d) and (e)

30 Agreement on Cooperation in the Area of Certification and Accreditation (CaA Side agreement) art. 1 and Annex III to Agreement on Cooperation in the Area of TBT and SPS (TBT SPS Side agreement) art. 1

31 CaA Side agreement art. 2 and Annex III to TBT SPS Side agreement art. 2

32 CaA Side agreement art. 3 and Annex III to TBT SPS Side agreement art. 3

33 FTA art. 6.7 and Agreement on Cooperation in the Area of Certification and Accreditation art. 5

34 According to Information provided by SECO (22.8.2013)

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions